Within the current context of personalized medicine, where physicians and policy makers must base their decisions on the highest level of available evidence in order to choose one out of multiple available treatment options, the present study aims to summarize the network of evidence supporting the treatment of patients with early and locally advanced HER2+ breast cancer in terms of overall survival (OS) and disease-free survival (DFS). This evidence concerns the gene ERBB2 and breast cancer.